The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.90
Bid: 29.10
Ask: 30.70
Change: 0.10 (0.34%)
Spread: 1.60 (5.498%)
Open: 29.80
High: 0.00
Low: 0.00
Prev. Close: 29.80
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of loan redemption

15 Apr 2016 15:53

RNS Number : 4054V
EKF Diagnostics Holdings PLC
15 April 2016
 

15 April 2016

EKF Diagnostics Holdings plc(the "Company" or the "Borrower")

 

Notice of loan redemption

 

EKF Diagnostics Holdings plc (AIM: EKF) announces that it has served notice to redeem the £3 million convertible loan ("Convertible Loan") from Zwanziger Family Ventures LLC (the "Lender").

 

Under the terms of the convertible loan the Borrower is entitled to repay the entire Convertible Loan giving the Lender at least 20 days' notice. The Lender has the right to serve a conversion notice on the Borrower at any time giving not less than 10 days' notice. If the Convertible Loan is converted, at the option of the Lender, the conversion price per share is 14.4 pence per share (being a 20 per cent. premium to the Company's share price on 22 December 2015).

 

North Atlantic Smaller Companies Investment Trust PLC ("NAIT") has agreed to provide to a loan facility of £3 million to EKF with interest accruing a LIBOR plus 5%, payable every 6 months in arrears, with security over the assets of the Company ranking behind HSBC (the "Loan"). There is no early re-payment penalty or ability to convert into ordinary shares of the Company. 

 

Christopher Mills as non-executive Chairman of the Company. Harwood Capital LLP is investment manager to NAIT. Harwood Capital LLP is a limited liability partnership of which Christopher Mills is a partner and Chief Investment Officer. Therefore the Loan constitutes a related party transaction. EKF's Directors, with the exception of Christopher Mills, consider, having consulted with its nominated adviser, that the terms of the transaction are fair and reasonable insofar as its shareholders are concerned.

 

EKF Diagnostics Holdings plc

Tel: 029 2071 0570

Julian Baines, CEO 

Richard Evans, FD & COO

Panmure Gordon (UK) Limited

Tel: 020 7886 2500

Robert Naylor (Corporate Finance)

Paul Fincham (Corporate Finance)

 

 

Walbrook PR Limited 

Tel: 020 7933 8780 or ekf@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZELFFQZFEBBL
Date   Source Headline
20th May 20147:01 amRNSAGM Statement
20th May 20147:00 amRNSSelah to provide Women's Health testing services
19th May 20143:13 pmRNSHolding(s) in Company - Replacement
16th May 20144:35 pmRNSHolding(s) in Company
15th May 20147:00 amRNSDirector/PDMR Shareholding
8th May 20141:10 pmRNSDirector/PDMR Shareholding
7th May 20147:00 amRNSSelah update
30th Apr 20147:01 amRNSHolding(s) in Company
23rd Apr 20144:46 pmRNSHolding(s) in Company
23rd Apr 20143:33 pmRNSHolding(s) in Company
17th Apr 20141:13 pmRNSDirector/PDMR Shareholding
15th Apr 20147:00 amRNSInvestor Teach-In
11th Apr 201411:33 amRNSResults of General Meeting and Total Voting Rights
10th Apr 20149:33 amRNSResult of Offer
31st Mar 20144:46 pmRNSDirector Resignation
31st Mar 201410:01 amRNSHolding(s) in Company
26th Mar 20144:18 pmRNSHolding(s) in Company
24th Mar 20147:00 amRNSHolding(s) in Company Replacement
20th Mar 201411:26 amRNSResult of the Placing
20th Mar 20147:00 amRNSProposed Acquisitions, Placing & Offer
12th Mar 20147:00 amRNSAcquisition of Separation Technology, Inc.
4th Mar 201411:16 amRNSTransfer of production
26th Feb 20147:00 amRNSFinal Results
18th Feb 20147:00 amRNSQuo-Lab registration in Mexico
17th Feb 20147:00 amRNSNotice of Results
28th Jan 201412:21 pmRNSAdditional Listing
27th Jan 20147:00 amRNSYear end trading update
24th Jan 20147:00 amRNSHolding(s) in Company
20th Jan 20147:00 amRNSPointMan enriches low-level mutations from blood
19th Nov 20137:00 amRNSAcute Kidney Injury marker development
4th Nov 20137:00 amRNSNew PointManT DNA enrichment products launched
30th Oct 20133:10 pmRNSHolding(s) in Company
8th Oct 20138:25 amRNSHolding(s) in Company
3rd Oct 20139:03 amRNSChange of Registered Office
25th Sep 201311:34 amRNSHolding(s) in Company
19th Sep 20137:28 amRNSInvestor Results Briefing
16th Sep 20137:00 amRNSInterim Results
14th Aug 20137:00 amRNSInvestor Teach-In
1st Aug 20137:00 amRNSTrading update
25th Jul 20137:00 amRNSInvestor Teach-In
23rd Jul 20137:00 amRNSSenior management update
4th Jul 201312:09 pmRNSHolding(s) in Company
26th Jun 20135:43 pmRNSAnalyst & Investor Teach-In
18th Jun 201310:17 amRNSDirector Share Transfer
11th Jun 20133:52 pmRNSAmendment to Long-Term Incentive Plan
15th May 20134:34 pmRNSResult of AGM
15th May 20137:00 amRNSAGM Statement
13th May 20137:00 amRNSFirst PointMan DNA enrichment products launched
15th Apr 20131:34 pmRNSPublication of Annual Report & Notice of AGM
18th Mar 20137:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.